Alpelisib (BYL719)
![]() |
- ₹0
- Product name: Alpelisib (BYL719)
- CAS: 1217486-61-7
- MF: C19H22F3N5O2S
- MW: 441.47
- EINECS:
- MDL Number:MFCD22417085
- Synonyms:(2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide;BYL-719 /BYL719;BLV-719;(S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-Methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxaMide;1,2-Pyrrolidinedicarboxamide, N1-[4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-, (2S)-;Alpelisib (BYL719);(2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide BYL-719;BYL-719 (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|
Properties
Density :1.391
storage temp. :Store at -20°C
solubility :≥22.07 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
form :White solid.
pka :6.29±0.70(Predicted)
color :Off-white to light yellow
InChIKey :STUWGJZDJHPWGZ-LBPRGKRZSA-N
SMILES :N1(C(NC2=NC(C)=C(C3C=CN=C(C(C)(C)C(F)(F)F)C=3)S2)=O)CCC[C@H]1C(N)=O
storage temp. :Store at -20°C
solubility :≥22.07 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
form :White solid.
pka :6.29±0.70(Predicted)
color :Off-white to light yellow
InChIKey :STUWGJZDJHPWGZ-LBPRGKRZSA-N
SMILES :N1(C(NC2=NC(C)=C(C3C=CN=C(C(C)(C)C(F)(F)F)C=3)S2)=O)CCC[C@H]1C(N)=O
Safety Information
Symbol(GHS): |
![]() |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Danger | ||||||||||||||
Hazard statements: |
|
||||||||||||||
Precautionary statements: |
|
Description
BYL719 is a selective inhibitor of phosphoinositide 3-kinase α (PI3Kα) that is equipotent against both wild type and several mutant isoforms (IC50s = 4.0-4.8 nM). It is less effective against PI3K isoforms β, γ, and δ (IC50s = 1,156, 250, and 290 nM) as well as a range of related kinases. BYL719 is effective in vivo, as it dose-dependently inhibits the growth of PI3Kα-dependent xenograft tumors in mice. Effectiveness against wild type and mutant PI3Kα-dependent tumors may be augmented by combination therapy with inhibitors of other kinases. Combination therapy may be necessary, as loss of downstream pathway components can confer clinical resistance to BYL719.More related product prices
BEZ235 (NVP-BEZ235, Dactolisib) 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE, 7-METHYL-2-(4-MORPHOLINYL)-9-[1-(PHENYLAMINO)ETHYL]- 871700-17-3 CAL-101 MK-2206 2HCl BKM120 (NVP-BKM120, Buparlisib) D-ERYTHRO-SPHINGOSINE Neratinib BI 2536 N-Hydroxy-4-[(1,2,3,4-tetrahydro-2-methyl-5H-pyrido[4,3-b]indol-5-yl)methyl]benzamide hydrochloride Fluoxetine hydrochloride 5-[(3-chlorophenyl)amino]-Benzo[c]-2,6-naphthyridine-8-carboxylic acid 918505-84-7 BML-275 Selumetinib KU-55933 Glucagon Receptor Antagonist IRelated product price
- D-ERYTHRO-SPHINGOSINE
₹10400-108498.98 - N-Hydroxy-4-[(1,2,3,4-tetrahydro-2-methyl-5H-pyrido[4,3-b]indol-5-yl)methyl]benzamide hydrochloride
₹9900-81674.63 - Fluoxetine hydrochloride
₹3311.7-53020.85
Suppliers and manufacturers
CLEARSYNTH LABS LTD.
A.J Chemicals
Pharmaffiliates Analytics and Synthetics P. Ltd
Taj Mahal Vision Chemicals Private Limited
SynZeal Research Pvt Ltd
Pharma Affiliates
Hangzhou FandaChem Co.,Ltd.